Nos tutelles

CNRS

IdEx

LabEx

Rechercher



Accueil > Membres > Les membres > Annuaire

Perrier Lionel

Contact
Address : Centre de Lutte Contre le Cancer Léon Bérard
Direction de la Recherche Clinique et de l’Innovation (DRCI)
28 rue Laënnec 69008 Lyon, France
lionel.perrier@lyon.unicancer.fr
Phone :+33 4 78 78 29 08 / Assistante +33 4 69 85 61 00
Fax :+33 4 78 78 59 45

ORCID iD : orcid.org/0000-0003-4487-8723
https://cv.archives-ouvertes.fr/lionel-perrier

Current position

  • in charge of the Innovations and strategies Unit, Clinical research and innovation direction (DRCI), Cancer Centre Léon Bérard, Lyon, France
  • Commission for Economic Evaluation and Public Health (CEESP), French National Authority for Health (HAS)
  • Member of the Human and Social Sciences Department (Dir Dr Marc Billaud), Cancer Centre Léon Bérard, Lyon, France
  • Lecturer (Lyon 2 University and Ecole Centrale de Lyon)
  • Hospinnomics chair associate researcher (Paris School of Economics, Assistance Publique - Hôpitaux de Paris)

Education

  • Habilitation (HDR), Lyon 2 University, 2010
  • PhD in Economics, Lyon 2 University, 2001

Fields of interest

  • Health Technology Assessment
  • Health care systems and reforms
  • Quality of life

Teaching and students

Teaching 2017-2018

  • Master RisE – Risques et Environnement, Ecole Centrale de Lyon
  • Master Analyse et Politiques Economiques, Lyon 2 University

PhD thesis supervision

  • Wilfried Guets, Modélisation de l’aide informelle : approches économiques et applications au dispositif innovant d’accompagnement et de répit des aidants de la métropole de Lyon, Lyon 2 University (since 2017), funding : Institut de Recherche en Santé Publique (IReSP)
  • Marius Huguet, Traitement du biais de sélection, estimation de l’effet causal et modélisation microéconomique : une application à la prise en charge des cancers de l’ovaire en France (co-supervision with X. Joutard, Aix Marseille University), Lyon 2 University (since 2016), funding : Lyon 2 University
  • Noémie Defourny, The cost of Radiotherapy in Europe : what does it cost, and how can these data be used to support innovation in European radiotherapy practice ? (co-supervision with Y. Lievens University of Gent), University of Gent, Belgium (since 2014), funding : European SocieTy for Radiotherapy & Oncology (ESTRO)
  • Maria Laura Silva, The role of the economic evaluations in health decision making : an application to influenza vaccination, Lyon 2 University (date of Defense 7th March 2016), funding : Science sans frontières ; Associate Professor, University of Bordeaux

Participation as referee / external examiner to PhD theses’ defense

  • Rana Maroun, Analyse comparative coût et efficacité des traitements du cancer du rein métastatique : analyse à partir des données de vie réelle et des données d’essais, Paris-Saclay University, 2018 (referee)
  • Omar Kanj, Evaluation économique de la prise en charge de l’endométriose, University Clermont Auvergne, 2017 (referee)
  • Sabri Hamana, Modélisation et simulation des flux d’informations ville-hôpital et de leur impact sur le parcours de soins, Ecole Nationale des Mines de Saint-Etienne, 2017 (external examiner)

Other responsabilities

Research programm coodinator

  • Coodinator (with S. Supiot) Place de l’acide ZOledronique dans la prise en charge par radiothérapie STERéotaxique des métastases vertébrales : Etude médico-économique de phase III, randomisée, contrôlée, en double aveugle contre placebo, AAP PRME 2016, Ministry of Health (DGOS) and the French National Cancer Institute (INCa) 2017
  • Coodinator (with H. Serrier and X. Xie) Evaluation of the very high sequencing platform built by the AURAGEN Consortium, AAP Mise en oeuvre et l’évaluation de projets pilotes de plateformes de séquençage très haut débit à visée sanitaire, Ministry of Health (DGOS), 2017
  • Coordinator Modélisation de l’aide informelle : approches économiques et applications au dispositif innovant d’accompagnement et de répit des aidants de la métropole de Lyon, AAP Handicap et perte d’autonomie, session 7 (IRESP), 2016
  • Coodinator (with R. de Crevoisier) Erectile dysfunction in low-risk prostate cancer : a phase III medico-economic study comparing brachytherapy to stereotactic body radiotherapy, PRME-K, French National Cancer Institute (INCa), 2016
  • Coodinator (with Sébastien Thureau) Economic evaluation of Extracranial stereotactic Body Radiation Therapy (SBRT) added to standard treatment versus standard treatment alone in solid tumors patients with ≤3 bone-only metastasis, PHRC-K, French National Cancer Institute (INCa), 2015
  • Coodinator (with R. de Crevoisier), Health economics evaluation of the adaptive radiotherapy strategy to decrease xerostomia in locally advanced oropharynx carcinoma, PRME-K, French National Cancer Institute (INCa), 2014
  • Coodinator (with I. Ray Coquard), Optimisation of disease management in patients with epithelial ovarian/fallopian tube/primary peritoneal carcinoma in France, PRME-K, French National Cancer Institute (INCa), 2014
  • Coordinator (with S. Baffert, I. Borget, I. Durand Zaleski, P.Marino), Economic impact of Next-generation sequencing (NGS) technologies, French National Cancer Institute (INCa), 2014
  • Coordinator Health information system evaluation, AAP PREPS SIPS, Ministry of Health, 2013
  • Coordinator (with JM Coindre) Economic evaluation of a second opinion in sarcoma, GIST, and desmoid tumour treatments , French National Cancer Institute (INCa), 2012

Expertise and other collective responsabilities

  • Member of the selection committee for grants “Programme de Recherche Médico-Economique (PRME-N)”, French Ministry of Health (since 2013)
  • Member of the Steering Committee GT 4 Innovation, French National Committee of the clinical research and innovation (Assemblée nationale des délégations à la recherche clinique et à l’innovation), since 2012
  • Member of the Abstract Review Committee for the ISPOR International Meetings
  • Coordonnateur du guide méthodologique Calcul et analyse des coûts hospitaliers, sous l’égide de la Conférence Nationale des Directeurs Généraux des CHU

Last publications

  • Perrier L, Rascle P, Morelle M, Toulmonde M, Ranchere Vince D, Le Cesne A, Terrier P, Neuville A, Meeus P, Farsi F, Ducimetière F, Blay JY, Ray Coquard I, Coindre JM. The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors : the experiences of the pathologists of the French Sarcoma Group. PlosOne. in press.
  • Morelle M, Plantier M, Dervaux B, Pagès A, Deniès F, Havet N, Perrier L ; French Costing Group. Methods for the analysis and treatment of cost data by micro- and gross-costing approaches. Rev Epidemiol Sante Publique. 2018 Mar 9. pii : S0398-7620(18)30158-5. doi : 10.1016/j.respe.2018.02.003.
  • Perrier L ; French Costing Group. Editorial. Rev Epidemiol Sante Publique. 2018 Feb 24. pii : S0398-7620(18)30159-7. doi : 10.1016/j.respe.2018.02.004.
  • Marino P, Touzani R, Perrier L, Rouleau E, Kossi DS, Zou Z, Charrier N, Goardon N, Preudhomme C, Durand-Zaleski I, Borget I, Baffert S. Cost of cancer diagnosis using Next-Generation Sequencing targeted gene panels in routine practice : a nationwide French study. European Journal of Human Genetics. 2018 Mar ;26(3):314-323. doi : 10.1038/s41431-017-0081-3.
  • Bibault JE, Morelle M, Huguet M, Perrier L, Giraud P. In reply to Jean-François Daisne, Sandra Nuyts, Fréderic Duprez and Benoît Bihin. International Journal of Radiation Oncology - Biology - Physics, 2018 Mar 1 ;100(3):808-809. doi : 10.1016/j.ijrobp.2017.11.042.
  • Bibault JE, Morelle M, Huguet M, Perrier L, Giraud P. In reply to Tallet et al. International Journal of Radiation Oncology - Biology - Physics, 2018 Feb 1 ;100(2):529-530. doi : 10.1016/j.ijrobp.2017.10.039.
  • Huguet M, Perrier L, Bally O, Benayoun D, De Saint Hilaire P, Beal Ardisson D, Morelle M, Havet N, Joutard X, Meeus P, Gabelle P, Provençal J, Chauleur C, Glehen O, Charreton A, Farsi F, Ray-Coquard IBeing treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France. BMC Health Serv Res. 2018 Jan 4 ;18(1):3. doi : 10.1186/s12913-017-2802-2.
  • Pérol O, Charbotel B, Perrier L, Bonnand S, Belladame E, Avrillon V, Rebattu P, Gomez F, Lauridant G, Pérol M, Fervers B. Systematic Screening for Occupational Exposures in Lung Cancer Patients : A Prospective French Cohort. Int J Environ Res Public Health. 2018 Jan 4 ;15(1). pii : E65. doi : 10.3390/ijerph15010065. -* Gnep K, Lizée T, Campillo-Gimenez B, Delpon G, Droupy S, Perrier L, de Crevoisier R. Toxicity and quality of life comparison of iodine 125 brachytherapy and stereotactic radiotherapy for prostate cancers. Cancer Radiother. 2017 Oct ;21(6-7):478-490. doi : 10.1016/j.canrad.2017.07.043.
  • Bibault JE, Dussart S, Pommier P, Morelle M, Huguet M, Boisselier P, Coche-Dequeant B, Alfonsi M, Bardet E, Rives M, Calugaru V, Chajon E, Noel G, Mecellem H, Servagi Vernat S, Perrier L, Giraud P. Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer : A Propensity Score-Weighted Analysis. Int J Radiat Oncol Biol Phys. 2017 Jun 27. pii : S0360-3016(17)33522-8. doi : 10.1016/j.ijrobp.2017.06.2456.
  • Penel-Page M, Marec-Bérard P, Morelle M, Bertrand A, Riberon C, Boyle H, Perrier L. Management of Febrile Neutropenias in Adolescents and Young Adults : A Cost-Minimization Analysis Between Adult Versus Pediatric Units. J Adolesc Young Adult Oncol. 2017 Jul 5. doi : 10.1089/jayao.2017.0035.
  • Rejeb O, Pilet C, Hamana S, Xie X, Durand T, Aloui S, Doly A, Biron P, Perrier L, Augusto V. Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation. Health Care Manag Sci. 2017 May 17. doi : 10.1007/s10729-017-9402-x.
  • Plantier M, Havet N, Durand T, Caquot N, Amaz C, Biron P, Philip I, Perrier L. Does adoption of electronic health records improve the quality of care management in France ? Results from the French e-SI (PREPS-SIPS) study. Int J Med Inform. 2017 Jun ;102:156-165. doi : 10.1016/j.ijmedinf.2017.04.002.
  • Varin M, Charbotel B, Pérol O, Perrier L, Massardier-Pilonchéry A, Bonnand S, Belladame E, Fort E, Avrillon V, Rebattu P, Pérol M, Fervers B. Assessment of a self-administered questionnaire identifying occupational exposures among lung cancer patients. Bull Cancer. 2017 Jun ;104(6):559-564. doi : 10.1016/j.bulcan.2017.03.014.
  • Havet N, Penot A, Morelle M, Perrier L, Charbotel B, Fervers B. Trends in occupational disparities for exposure to carcinogenic, mutagenic and reprotoxic chemicals in France 2003-10.Eur J Public Health. 2017 Jun 1 ;27(3):425-432. doi : 10.1093/eurpub/ckx036.
  • Sambou C, Guillemaut S, Morelle M, Achache A, Le Corroller AG, Perol D, Perrier L. ISO 9001 certification of innovation and clinical research departments : Extending the scope of health assessment. Rev Epidemiol Sante Publique. 2017 Apr ;65(2):159-167. doi : 10.1016/j.respe.2016.12.026.
  • Havet N, Penot A, Morelle M, Perrier L, Charbotel B, Fervers B. Varied exposure to carcinogenic, mutagenic, and reprotoxic (CMR) chemicals in occupational settings in France. Int Arch Occup Environ Health. 2017 Feb ;90(2):227-241.
  • Plantier M, Havet N, Durand T, Caquot N, Amaz C, Philip I, Biron P, Perrier L. Does adoption of electronic health records improve organizational performances of hospital surgical units ? Results from the French e-SI (PREPS-SIPS) study. Int J Med Inform. 2017 Feb ;98:47-55. doi : 10.1016/j.ijmedinf.2016.12.002.
  • Perrier L, Morelle M, Huguet M, Dussart S, Giraud P. In Reply to Escande et al. Int J Radiat Oncol Biol Phys. 2017 Jan 1 ;97(1):205-208.
  • Ceraulo A, Ouziel A, Lavergne E, Perrier L, Decouvelaere AV, Chotel F, Thiesse P, Marec-Berard P. Percutaneous guided biopsy for diagnosing suspected primary malignant bone tumors in pediatric patients : a safe, accurate, and cost-saving procedure. Pediatr Radiol. 2017 Feb ;47(2):235-244. doi : 10.1007/s00247-016-3735-3.